Hydroxyethylrutosides (HER), also known as oxerutins, O-beta-hydroxyethyl-rutosides, or simply HR, are hydroxyethyl derivatives of rutosides, a class of compounds derived from the natural flavonoid rutin. These compounds are semisynthetic and are not naturally present in foods. The only available form of intake is through pharmaceutical or dietary supplements.
Chemical and Structural Classification
Hydroxyethylrutosides are chemically modified versions of rutin in which hydroxyethyl groups are introduced to enhance solubility and bioavailability. The major compounds in this group include:
- Monoxerutin
- Dihydroxyethylrutoside
- Troxerutin
- Tetrahydroxyethylrutoside
These derivatives are grouped together under the name oxerutins, which are typically standardized mixtures in medicinal preparations.
Medical Uses
Hydroxyethylrutosides have been widely studied and used in vascular medicine, primarily for improving venous tone and capillary resistance. They are most commonly prescribed for:
- Chronic venous insufficiency (CVI) – a condition characterized by impaired blood return from the legs, leading to swelling, pain, and varicose veins.
- Hypertensive microangiopathy – a microvascular complication of hypertension affecting small blood vessels.
The compounds are believed to work by reducing vascular permeability, thereby decreasing capillary leakage and tissue edema. Commercial preparations include:
- Venoruton (first marketed in Switzerland in 1962)
- Relvène (France, 1967)
- Paroven
Hydroxyethylrutosides are often used as a plant-derived alternative to horse chestnut extract (containing aescin) for venotonic therapy.
Dosage and Administration
Typical oral doses range around 1,000 mg per day, often divided into two or three administrations. The drug is available in capsule, tablet, and topical gel forms. While hydroxyethylrutosides are considered safe for most adults, their efficacy and long-term outcomes require further large-scale studies.
Pharmacological Actions
- Capillary stabilization: Strengthens capillary walls and reduces abnormal permeability.
- Anti-edematous effect: Decreases swelling in chronic venous disorders.
- Antioxidant properties: Scavenges free radicals and prevents oxidative damage to vascular endothelium.
Hydroxyethylrutosides have also been studied for protective effects against adriamycin-induced toxicity in laboratory animals, suggesting potential use as a vascular protectant during chemotherapy.
Research and Clinical Findings
Experimental models have shown that hydroxyethylrutosides may mitigate the cardiotoxic effects of adriamycin (doxorubicin) in rats by improving microcirculatory dynamics. However, these findings remain preclinical, and further studies are needed to confirm efficacy in humans.
Safety and Precautions
Hydroxyethylrutosides are generally well tolerated, with few reported side effects. Mild gastrointestinal discomfort, headaches, or allergic reactions may occur in rare cases. As with most flavonoid derivatives, caution is advised for pregnant or breastfeeding women unless prescribed by a physician.
In summary, Hydroxyethylrutoside is a semisynthetic flavonoid developed to improve vascular health by enhancing capillary integrity and reducing fluid leakage. Its use in managing chronic venous insufficiency and related disorders makes it a key therapeutic option in phytochemical-based vascular treatments.
